Study of the effectiveness of voriconazole in the treatment of Aspergillus fumigatus associated asthma: a randomised double blinded, placebo controlled trial

niversity Hospitals of Leicester NHS Trust (UK)0 个研究点目标入组 70 人开始时间: 2009年1月30日最近更新: 2016年10月17日

适应症

试验速览

暂无简介。

•1. Symptoms consistent with a diagnosis of asthma
•2. A clinical phenotype consistent with AF associated asthma in the opinion of at least two consultant members of the study team
•3. Evidence of immune sensitisation to AF (either positive AF IgE, positive SPT to AF or positive AF IgG)
•4. A raised peripheral blood eosinophil count or sputum eosinophil count of more than 10% on at least one occasion in the last two years
•5. AF in sputum on two occasions within the six months prior to entry into the study
•6. At least two severe exacerbations in the previous 12 months (defined as a requirement for a course of high dose oral steroids for treatment of their asthma)
•7. Aged above 18 years, both male and female

•1. Unable to give informed consent
•2. Pregnancy or possibility of becoming pregnant during the treatment phase of the study
•3. A primary diagnosis (in the opinion of the study team) of chronic obstructive pulmonary disease (COPD) (smoking related obstructive disease)
•4. Any conditions or drug interactions that in the opinion of the study team could lead to harmful interactions with voriconazole
•5. Allergy to voriconazole
•6. Poor compliance
•7. Inability to produce sputum

发起方

niversity Hospitals of Leicester NHS Trust (UK)